- Home
- FBK vs VRDN Comparison
FBK vs VRDN Comparison
Compare FBK & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBK | VRDN |
|---|---|---|
| Founded | 1906 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2016 | 2014 |
Fundamental Metrics
Financial Performance| Metric | FBK | VRDN |
|---|---|---|
| Price | $51.15 | $27.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $61.75 | $40.92 |
| AVG Volume (30 Days) | 238.2K | ★ 1.0M |
| Earning Date | 04-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | $43.54 | $27.65 |
| Revenue Next Year | $7.86 | $253.29 |
| P/E Ratio | $20.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.83 | $9.90 |
| 52 Week High | $62.37 | $34.29 |
Technical Indicators
Market Signals| Indicator | FBK | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 30.55 | 41.41 |
| Support Level | $49.74 | $26.31 |
| Resistance Level | $55.81 | $33.71 |
| Average True Range (ATR) | 1.42 | 1.29 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 25.07 | 21.64 |
Price Performance
Historical ComparisonAbout FBK FB Financial Corporation
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).